ClinicalTrials.gg
Not yet recruitingNCT07938424Updated Nov 16, 2026

Soft Tissue Augmentation in Maxillary Anterior Immediate Implant Sites

An interventional study of VCMX in Edentulous Alveolar Ridge, sponsored by Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University. Not yet recruiting. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University · Not applicable, Interventional, and Treatment

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
46
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The thickness of buccal soft tissue at the maxillary anterior implant is important for the esthetics and health of implant. However, the thickness at the anterior tooth site always shows thin biotype. So, autogenous connective tissue graft (CTG) is used to augment tissue thickness during immediate implant placement. However, it is pain and not acceptable by the patient. Soft tissue substitutes are used to replace CTG. The purpose of this RCT is to compare the volume-- stable collagen matrix (VCMX) with CTG at the maxillary anterior site.

02

Conditions studied

  • Edentulous Alveolar Ridge

Keywords

  • immediate implant
  • soft tissue graft
03

In context

Lead sponsor

Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University is the lead sponsor of 165 studies on the registry; 74 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The labial bone wall of the immediate implant site is intact (thickness less than 1 mm), or the patient has a thin gingival biotype;
  2. No labial contour concavity/deficiency;
  3. Adjacent teeth and opposing teeth are healthy;
  4. Sufficient mesiodistal space and sufficient occlusal distance;
  5. The labial bone wall remains intact after minimally invasive tooth extraction;
  6. The patient voluntarily participates in the study and signs the form

Exclusion criteria

Exclusion Criteria:

  1. Patients with severe uncontrolled periodontitis;
  2. Heavy smokers, more than 10 cigarettes per day;
  3. Other patients judged by the investigator to be unsuitable for immediate implant placement.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
46 participants (estimated)

Study arms

  • Experimental
    test group

    Geistlich Fibro-Gide will be used to augment buccal soft tissue thickness

    Procedure: VCMX

  • No intervention
    control group

    autogenous connective tissue graft, harvest from the palatal site

Interventions

  • ProcedureVCMX

    A VISTA incision combined with a tunnel flap. Fibro-Gide will be placed tension-free within the flap

06

What researchers measure

Primary outcomes

  1. Soft tissue contour changes on the labial aspect of the implant site.

    Intraoral scan data were used, and the T5 and Tpre scans were superimposed. A region of interest (ROI) was selected on the labial aspect, and the contour change (Dvol) between T5 and Tpre was calculated. The thickness change was calculated as Dd \[mm\] = Dvol \[mm³\] / area \[mm²\] (Nimwegen et al.). The ROI was defined using the mesial and distal papilla margins of the adjacent teeth, the mucogingival junction (MGJ) apically, and the crown margin coronally as anatomical reference structures to determine the boundaries of the region. Two investigators performed the measurements independently, and inter-examiner agreement was calculated

    Time frame: 3 months after surgery

Secondary outcomes

  1. time of soft tissur graft

    from the flap to the final suture. tooth extraction, osteotomy, implant placement, and bone graft placement will not be included

    Time frame: during the surgery

07

Study locations

No study locations are listed for this record.

08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for Jan 2028, 14 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 10, 2026
First posted
Nov 16, 2026
StartEst.
Nov 1, 2026
Primary completionEst.
Jan 31, 2028
CompletionEst.
Jan 31, 2028
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07938424
Responsible party
Junyu Shi (Associate professor, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University) — Principal investigator
First posted
Nov 16, 2026
Start date
Nov 1, 2026 (estimated)
Primary completion
Jan 31, 2028 (estimated)
Completion
Jan 31, 2028 (estimated)
Last update
Nov 16, 2026

Study contacts

Xiao-Jiao Fu
Contact
2521377229@qq.com
+8618810982837

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion